{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:31:44Z","timestamp":1771104704192,"version":"3.50.1"},"reference-count":36,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,12,3]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The carbon footprint of severe asthma and the impact of biologic therapy in this population is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective cohort study in adults with severe asthma, using data from the Northern Ireland Regional Severe Asthma Service (September 2015\u2013November 2021). We calculated annual greenhouse gas (GHG) emissions (carbon dioxide equivalent) for asthma-related medications and healthcare resource utilisation, compared patient characteristics by GHG quartile, calculated GHG change post-biologic initiation, and explored the relationship between GHG change and clinical response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 303 patients with severe asthma, mean\u00b1<jats:sc>sd<\/jats:sc>GHG emissions were 474\u00b1431\u2005kg, largely driven by SABA use (50.7%) and emergency department (ED) visits\/inpatient admissions (21.0%). Those with highest-quartile GHG emissions were more likely to have uncontrolled disease (Asthma Control Questionnaire-5 score 3.5<jats:italic>versus<\/jats:italic>2.5; p&lt;0.001), be more deprived (46.1%<jats:italic>versus<\/jats:italic>25.0%; p=0.029) and have depression\/anxiety (35.5%<jats:italic>versus<\/jats:italic>14.7%; p=0.002)<jats:italic>versus<\/jats:italic>those with lowest-quartile GHG emissions. Among patients who received a biologic (n=213), modest GHG reductions (\u221228.0\u00b1286\u2005kg; p=0.15) were observed, largely driven by a reduction in ED\/hospitalisation-related GHG emissions (\u221259.3\u00b1224\u2005kg; p&lt;0.001). SABA-related GHG emissions were relatively unchanged (\u22126.1\u00b1138\u2005kg; p=0.518). Total GHG emissions were 72.4\u00b1352\u2005kg (p=0.044) lower than baseline at 4\u2005years post-biologic initiation. Although there was substantial clinical improvement post-biologic initiation, this was not associated with GHG reductions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Severe asthma is associated with substantial GHG emissions, primarily driven by SABA use and emergency care utilisation. Although GHG emissions were lower post-biologic, largely due to a reduction in emergency care, the changes in GHG emissions were modest and SABA use was relatively unchanged. An improved understanding of the factors driving elevated GHG emissions is required.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.01009-2024","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T04:01:58Z","timestamp":1734062518000},"page":"01009-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the carbon footprint of severe asthma and change after biologic therapy initiation: an analysis of Northern Irish data"],"prefix":"10.1183","volume":"11","author":[{"given":"John","family":"Busby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Khezrian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soram","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trung N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"2025062304002048000_11.3.01009-2024.1","unstructured":"World Health Organization . Climate change: key facts. 2023. www.who.int\/news-room\/fact-sheets\/detail\/climate-change-and-health Date last accessed: 28 February 2025."},{"key":"2025062304002048000_11.3.01009-2024.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1011612108"},{"key":"2025062304002048000_11.3.01009-2024.3","doi-asserted-by":"publisher","DOI":"10.1016\/S2542-5196(20)30271-0"},{"key":"2025062304002048000_11.3.01009-2024.4","unstructured":"NHS England and NHS Improvement . Delivering a \u2018Net-Zero\u2019 National Health Service. 2022. www.england.nhs.uk\/greenernhs\/wp-content\/uploads\/sites\/51\/2022\/07\/B1728-delivering-a-net-zero-nhs-july-2022.pdf Date last accessed: 28 February 2025."},{"key":"2025062304002048000_11.3.01009-2024.5","unstructured":"Faculty of Public Health Special Interest Group \u2013 Sustainable Development . The NHS carbon footprint. 2024. www.fph.org.uk\/media\/3126\/k9-fph-sig-nhs-carbon-footprint-final.pdf Date last accessed: 28 February 2025."},{"key":"2025062304002048000_11.3.01009-2024.6","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2063603"},{"key":"2025062304002048000_11.3.01009-2024.7","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220259"},{"key":"2025062304002048000_11.3.01009-2024.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072328"},{"key":"2025062304002048000_11.3.01009-2024.9","unstructured":"Asthma+Lung UK . What is severe asthma? 2022. www.asthmaandlung.org.uk\/conditions\/severe-asthma\/what-severe-asthma Date last accessed: 28 February 2025."},{"key":"2025062304002048000_11.3.01009-2024.10","unstructured":"Asthma+Lung UK . Types of asthma. 2024. www.asthmaandlung.org.uk\/conditions\/asthma\/types-asthma Date last accessed: 28 February 2025."},{"key":"2025062304002048000_11.3.01009-2024.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00819-2023"},{"key":"2025062304002048000_11.3.01009-2024.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215168"},{"key":"2025062304002048000_11.3.01009-2024.13","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213744"},{"key":"2025062304002048000_11.3.01009-2024.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01705-2023"},{"key":"2025062304002048000_11.3.01009-2024.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00856-2023"},{"key":"2025062304002048000_11.3.01009-2024.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02760-2021"},{"key":"2025062304002048000_11.3.01009-2024.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-218088"},{"key":"2025062304002048000_11.3.01009-2024.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028763"},{"key":"2025062304002048000_11.3.01009-2024.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025062304002048000_11.3.01009-2024.20","unstructured":"Sustainable Healthcare Coalition . Sustainable Care Pathways Guidance. 2023. https:\/\/shcoalition.org\/sustainable-care-pathways-guidance Date last accessed: 28 February 2025."},{"key":"2025062304002048000_11.3.01009-2024.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclepro.2019.117733"},{"key":"2025062304002048000_11.3.01009-2024.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000571"},{"key":"2025062304002048000_11.3.01009-2024.23","unstructured":"Office for National Statistics . SRS Output Checking Guidance Document Work Strand: Statistical Disclosure Control. 2022. https:\/\/www.ons.gov.uk\/file?uri=\/aboutus\/whatwedo\/statistics\/requestingstatistics\/secureresearchservice\/gettingyourresearchoutputsapproved\/srsoutputcheckingguidance.pdf Date last accessed: 28 February 2025."},{"key":"2025062304002048000_11.3.01009-2024.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02259-2019"},{"key":"2025062304002048000_11.3.01009-2024.25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/02770903.2023.2289169","article-title":"Exacerbations, treatment patterns, utilization, and costs before and after initiating of benralizumab for the treatment of severe eosinophilic asthma","volume":"61","author":"Smith","year":"2024","journal-title":"J Asthma"},{"key":"2025062304002048000_11.3.01009-2024.26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/resp.13830","article-title":"Bronchial thermoplasty versus mepolizumab: comparison of outcomes in a severe asthma clinic","volume":"25","author":"Langton","year":"2020","journal-title":"Respirology"},{"key":"2025062304002048000_11.3.01009-2024.27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01233-0"},{"key":"2025062304002048000_11.3.01009-2024.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02583-2021"},{"key":"2025062304002048000_11.3.01009-2024.29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/02770903.2020.1761382","article-title":"Identifying the drivers of patients\u2019 reliance on short-acting \u03b22-agonists in asthma","volume":"58","author":"Blakeston","year":"2021","journal-title":"J Asthma"},{"key":"2025062304002048000_11.3.01009-2024.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002247"},{"key":"2025062304002048000_11.3.01009-2024.31","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15135"},{"key":"2025062304002048000_11.3.01009-2024.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01046-2019"},{"key":"2025062304002048000_11.3.01009-2024.33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00160-2024"},{"key":"2025062304002048000_11.3.01009-2024.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02106-2021"},{"key":"2025062304002048000_11.3.01009-2024.35","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jaip.2022.04.015","article-title":"Perceptions on home-administration of biologics in the context of severe asthma: an international qualitative study","volume":"10","author":"Flokstra-de Blok","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025062304002048000_11.3.01009-2024.36","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/all.13370","article-title":"Comorbid \u2018treatable traits\u2019 in difficult asthma: current evidence and clinical evaluation","volume":"73","author":"Tay","year":"2018","journal-title":"Allergy"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01009-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:00:32Z","timestamp":1750676432000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01009-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1183\/23120541.01009-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01009-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}